EP Patent

EP4209592A1 — Serpinc1 irna compositions and methods of use thereof

Assigned to Genzyme Corp · Expires 2023-07-12 · 3y expired

What this patent protects

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpincl and methods of treating subjects having a bleeding disorder, such a…

USPTO Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpincl and methods of treating subjects having a bleeding disorder, such as a hemophilia.

Drugs covered by this patent

Patent Metadata

Patent number
EP4209592A1
Jurisdiction
EP
Classification
—
Expires
2023-07-12
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.